Finding new treatments for nerve pain using specific inhibitors
Official title: Identification of novel lead EphB1/2 tyrosine kinase inhibitors targeting peripheral neuropathic pain
Funded at Texas Tech University Health Scis Center · NIH-11047339 · Data updated 2026-11-12
This study is looking for a new, safer way to help people with chronic nerve pain by testing a combination of existing antibiotics that might ease their symptoms without using opioids.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas Tech University Health Scis Center NIH-funded |
| Lab location | 1 site (Lubbock, United States) |
| Project start | March 1, 2025 |
| Project end | February 28, 2030 |
| Funding year | 2025 |
| Award (this year) | $387,500 |
| NIH project number | 1R01NS136485-01A1 |
| Project ID | NIH-11047339 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals suffering from chronic peripheral neuropathic pain.
✕Less likely to help
Patients with acute pain conditions or those not experiencing neuropathic pain may not benefit from this research.
What this research studies
This research focuses on developing new, non-opioid therapies for managing chronic peripheral neuropathic pain, which is a significant public health issue due to the opioid crisis. The team will investigate the role of EphB1 tyrosine kinase inhibitors in reversing pain symptoms, using a combination of existing antibiotics that have shown promise in preliminary studies. By examining how these inhibitors affect pain pathways, the research aims to provide a safer alternative to traditional pain medications. Patients may benefit from a new treatment option that does not carry the risks associated with opioids.
Why it matters
Potential benefit: If successful, this research could lead to effective, non-addictive treatments for chronic nerve pain.
How similar studies have gone: Previous studies have shown promise in using EphB1 inhibitors for pain management, indicating potential for success in this approach.
Where this research is happening
-
Texas Tech University Health Scis Center
Lubbock, United States Active
Researchers
- Principal investigator: Ahmed, Mahmoud Salama — Texas Tech University Health Scis Center
- Study coordinator: Ahmed, Mahmoud Salama
Related research
Other NIH-funded projects on the same topics.
-
Peripheral nerve stimulation for chronic neuropathic pain in a new mechanistic trial
A study at Stanford tests whether a painless-sounding electrical nerve treatment helps people with long-standing neuropathic pain when added to standard care.
-
Keratinocytes and nerve pain in chemotherapy patients
A study tests a new approach to reduce painful nerve damage from chemotherapy by targeting skin cells called keratinocytes.
-
High-frequency brain stimulation for trigeminal neuropathic pain
A large, multi-site trial tests a non-invasive brain stimulation method to relieve chronic facial nerve pain for adults who have not found relief from other treatments.
-
Programmable lithium-delivery devices for pain relief without motor loss
A new bioelectronic system uses a safe lithium source and AI-powered control to deliver targeted pain relief for neuropathic pain, aiming to spare motor function.
-
Glial-nerve conversations in neuropathic pain and diabetes
This grant looks at how supportive brain and nerve cells communicate with pain-sensing neurons to understand and reduce chronic nerve pain in people.
-
Parmodulins with Low Abuse Potential for Neuropathic Pain
A new class of pain medicines called parmodulins is being studied to help people with nerve-pain pain without high abuse risk.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.